Rheumatology 1999; 38: 1045-1049
© 1999 British Society for Rheumatology
Reviews |
Assessing patients with lupus: towards a drug responder index
Centre for Rheumatology/Bloomsbury Rheumatology Unit, Middlesex Hospital, London and
1 Division of Arthritis and Connective Tissue Diseases, Northwestern University, Chicago, IL 60611-3008, USA
Correspondence to:
D. Isenberg, Centre for Rheumatology/Bloomsbury Rheumatology Unit, Middlesex Hospital, Arthur Stanley House, 40–50 Tottenham Street, London W1P 9PG, UK.
 |
Introduction |
|---|
The remarkable diversity of clinical features that are evident in patients with systemic lupus erythematosus (SLE) demands particular vigilance on the part of the clinician attempting to assess and treat this complex, but fascinating, disease. Although virtually any symptom one cares to think of may be due to active lupus (particularly in the central nervous system), the physician must also guard against the fallacy that every clinical problem experienced by a patient with lupus is due to the disease. In this review, we will put forward the view that in order to understand the totality of the effect of a disease like lupus upon a patient, measures are needed that distinguish disease activity (implying that the problems can be corrected), damage (meaning permanent change) and the patient's own perception of their health status.
|
Practical assessment of patients with lupus in the clinic or hospital ward |
|---|
A comprehensive approach in a chronic disease characterized by exacerbations and remissions is needed in all settings
|
What are the goals and challenges of assessment in lupus patients? |
|---|
|
What should be assessed? |
|---|
|
Formal assessment of disease activity in SLE |
|---|
|
Assessment of damage in SLE |
|---|
|
Assessing health status in SLE |
|---|
|
Future developments |
|---|
|
Acknowledgments |
|---|
|
References |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S-W Lee, M-C Park, Y-B Park, and S-K Lee E/E' ratio is more sensitive than E/A ratio for detection of left ventricular diastolic dysfunction in systemic lupus erythematosus Lupus, March 1, 2008; 17(3): 195 - 201. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Kocis Prasterone Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2201 - 2210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A C Cordeiro and D A Isenberg Treatment of inflammatory myopathies. Postgrad. Med. J., July 1, 2006; 82(969): 417 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Doria, S. Rinaldi, M. Ermani, F. Salaffi, L. Iaccarino, A. Ghirardello, S. Zampieri, S. Della Libera, G. Perini, and S. Todesco Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants Rheumatology, December 1, 2004; 43(12): 1580 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stoll, N. Sutcliffe, J. Mach, R. Klaghofer, and D. A. Isenberg Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study Rheumatology, August 1, 2004; 43(8): 1039 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I A Lisukov, S A Sizikova, A D Kulagin, I V Kruchkova, A V Gilevich, L P Konenkova, E V Zonova, E R Chernykh, O Y Leplina, T N Sentyakova, et al. High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus Lupus, February 1, 2004; 13(2): 89 - 94. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Isenberg, E. Allen, V. Farewell, M. R. Ehrenstein, M. G. Hanna, I. E. Lundberg, C. Oddis, C. Pilkington, P. Plotz, D. Scott, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease Rheumatology, January 1, 2004; 43(1): 49 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O Nived, G Sturfelt, M H Liang, and P De Pablo The ACR nomenclature for CNS lupus revisited Lupus, December 1, 2003; 12(12): 872 - 876. [Abstract] [PDF]
|
|
|
|
|
|
D Isenberg and R Smeenk Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now? Lupus, December 1, 2002; 11(12): 797 - 800. [Abstract] [PDF]
|
|
|
|
|
|
C. Gordon Long-term complications of systemic lupus erythematosus Rheumatology, October 1, 2002; 41(10): 1095 - 1100. [Full Text] [PDF]
|
|
|
|
|
|
P. Maddison Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition Rheumatology, September 1, 2002; 41(9): 965 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. van Vollenhoven Dehydroepiandrosterone in the treatment of systemic lupus erythematosus Rheumatology, August 1, 2000; 39(8): 929 - 930. [Full Text] [PDF]
|
|